#United States #dividends #medical technology #Franklin Lakes #Becton Dickinson

BD Board Declares Quarterly Dividend

On July 22, 2025, the Board of Directors of Becton, Dickinson and Company, commonly known as BD (NYSE: BDX), revealed significant news that underscores the company’s steadfast commitment to its shareholders. BD’s Board announced a quarterly dividend of $1.04 per common share. This dividend will be payable on September 30, 2025, to all shareholders on record as of September 8, 2025. With this declaration, the company sets an annual dividend rate of $4.16 per share, further solidifying its promise to provide consistent returns to its investors.

BD stands as one of the foremost global leaders in the medical technology sector. The company's mission revolves around advancing global health through the improvement of medical discovery, diagnostics, and the delivery of care. BD supports the dedicated healthcare professionals on the frontlines by developing innovative technologies, services, and solutions aimed at enhancing both clinical therapy and the overall clinical processes employed by healthcare providers.

With a dedicated workforce of over 70,000 employees, BD demonstrates a passion for catalyzing change in the healthcare sector. The company is focused on improving the safety and efficiency of care delivery. By enabling laboratory scientists to accurately detect diseases and empowering researchers to develop cutting-edge diagnostics and therapeutics, BD plays a pivotal role in shaping healthcare's future.

BD's presence spans virtually every country on the globe. The organization collaborates with various partners to tackle some of the most pressing global health challenges. Through close cooperation with customers, BD continually works to achieve better health outcomes, reduce costs, enhance operational efficiency, improve safety, and expand access to quality healthcare.

The declared dividend serves not just as a financial benefit to the shareholders but also as an indicator of BD's robust financial health and its ongoing strategy to invest in long-term growth and sustainability within the healthcare landscape. As one of the largest medical technology companies worldwide, BD's ongoing innovations are vital for enhancing healthcare delivery and outcomes.

In conclusion, BD’s quarterly dividend declaration reinforces the company's promise to its stakeholders, ensuring that they reap the rewards of their investment while supporting its mission to improve global health through innovative medical technology. For more details regarding BD and its innovative health solutions, interested readers can visit bd.com, or connect with them on social media platforms including LinkedIn, Twitter, and Instagram.

Company Overview: BD

Becton, Dickinson and Company is not only a symbol of medical innovation but also a cornerstone of health advancements worldwide. By addressing and solving some of the most challenging health issues, BD reaffirms the critical role of technology in enhancing healthcare quality and efficiency. As investors, stakeholders, and the healthcare community recognize BD's dedication, the company is well-positioned for continued growth in the ever-evolving medical landscape.